{"url":"https://newsforagent.com/news/2026-11-16/omeros-q3-revenue-adjusted-earnings","markdown_url":"https://newsforagent.com/news/2026-11-16/omeros-q3-revenue-adjusted-earnings.md","title":"Omeros Q3 Revenue Misses Estimates at $35.9 Million","headline":"Omeros Posts $35.9 Million Q3 Revenue, Below FactSet Estimate, and Swings to Adjusted Earnings","description":"Omeros reported $35.9 million in third-quarter revenue, short of the $37.3 million FactSet estimate, while swinging to adjusted earnings and lifting YARTEMLEA sales 26%.","section":"Earnings & Results","published_at":"2026-11-16T22:03:10+00:00","modified_at":"2026-11-16T22:03:10+00:00","author":"News Desk","key_takeaways":["Omeros reported third-quarter revenue of $35.9 million, missing the FactSet estimate of $37.3 million.","YARTEMLEA net revenue rose 26% to $35.9 million in the quarter.","Omeros recorded a GAAP net loss of $57.4 million, or $0.79 per share, including a $62.0 million non-cash derivative remeasurement charge."],"companies":[{"name":"Omeros","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000wi3/omeros","website":"http://www.omeros.com"}],"source":{"publisher":"MarketScreener","title":"Omeros Q3 Swings to Adjusted Earnings","url":"https://www.marketscreener.com/news/omeros-q3-swings-to-adjusted-earnings-ce785edfdc89fe20"},"other_sources":[],"tags":["Earnings & Results","Omeros"],"body_markdown":"[Omeros](https://akta.pro/company-profiles/0000wi3/omeros) reported third-quarter revenue of $35.9 million, missing the FactSet estimate of $37.3 million, and swung to adjusted earnings, [MarketScreener](https://www.marketscreener.com/news/omeros-q3-swings-to-adjusted-earnings-ce785edfdc89fe20) reported on November 16, 2026. The company's stock closed at $16.68, down 4.63% from the prior close.\n\n## Omeros Swings to Adjusted Profit as YARTEMLEA Sales Climb\n\nOmeros is a commercial-stage biopharmaceutical company that develops therapies for complement-mediated diseases, central nervous system disorders and oncology, and sells YARTEMLEA, which it describes as the only FDA-approved therapy for TA-TMA, according to company records.\n\nYARTEMLEA net revenue rose 26% to $35.9 million in the quarter, TradingView reported. Omeros posted a GAAP net loss of $57.4 million, or $0.79 per share, which included a $62.0 million non-cash derivative remeasurement charge. Operating cash flow was $13.3 million, and the company held $95.3 million in cash and short-term investments.\n\nMarketScreener reported that Omeros swung to adjusted earnings in the quarter and did not disclose further details on the adjusted figure.\n\n## YARTEMLEA Billing and Launch Figures\n\nOmeros launched YARTEMLEA commercially in the US on January 2, 2026, and reached cash-flow positivity in the first quarter of 2026 with 30 accounts ordering product and $9.89 million in first-quarter sales, according to akta.pro [company records](https://akta.pro/company-data). CMS assigned a permanent HCPCS J-code, J1289, for YARTEMLEA effective July 1, 2026, which the records describe as streamlining Medicare and commercial payer billing and reimbursement at the $36,000 per-vial price point.\n\n## EMA Opinions and a Securities Investigation\n\nPomerantz LLP is investigating Omeros for potential securities fraud following two European Medicines Agency negative opinions on its narsoplimab marketing authorisation application, GlobeNewswire reported. The stock fell 19.12% to $8.67 after the first negative opinion and 13.78% to $16.20 after a re-examination.\n\nOmeros announced on November 10, 2026, that it would report third-quarter results after market close on November 16 and host a conference call and webcast at 4:30 p.m. Eastern Time, FinancialContent Business Page reported.\n\n## Omeros Pipeline Timeline\n\nOmeros said its OncotoX-AML cancer therapeutic platform achieved up to 99% reduction in myeloid progenitor cells in nonhuman primate studies and is advancing to IND-enabling studies, with a first-in-human trial targeted for late 2027, according to [its announcement](http://www.omeros.com).\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}